Literature DB >> 16437675

Correlation between the expressions of gastrin, somatostatin and cyclin and cyclin-depend kinase in colorectal cancer.

Pei Wu1, Jia-Ding Mao, Jing-Yi Yan, Jing Rui, You-Cai Zhao, Xian-Hai Li, Guo-Qiang Xu.   

Abstract

AIM: To explore the correlation between the expressions of gastrin (GAS), somatostatin (SS) and cyclin, cyclin-dependent kinase (CDK) in colorectal cancer, and to detect the specific regulatory sites where gastrointestinal hormone regulates cell proliferation.
METHODS: Seventy-nine resected large intestine carcinomatous specimens were randomly selected. Immunohistochemical staining for GAS, SS, cyclin D1, cyclin E, cyclin A, cyclin B1, CDK2 and CDK4 was performed according to the standard streptavidin-biotin-peroxidase (S-P) method. According to the semi-quantitative integral evaluation, SS and GAS were divided into high, middle and low groups. Cyclin D1, cyclin E, cyclin A, cyclin B1, CDK2, CDK4 expressions in the three GAS and SS groups were assessed.
RESULTS: The positive expression rate of cyclin D1 was significantly higher in high (78.6%, 11/14) and middle GAS groups (73.9%, 17/23) than in low GAS group (45.2%, 19/42) (P<0.05, c2(high vs low) = 4.691; P<0.05, c2(middle vs low) = 4.945). The positive expression rate of cyclin A was significantly higher in high (100%, 14/14) and middle GAS groups (82.6%, 19/23) than in low GAS group (54.8%, 23/42) (P<0.01, c2(high vs low) = 9.586; P<0.05, c2(middle vs low) = 5.040). The positive expression rate of CDK2 was significantly higher in high (92.9%, 13/14) and middle GAS groups (87.0%, 20/23) than in low GAS group (50.0%, 21/42) (P<0.01, c2(high vs low) = 8.086; P<0.01, c2(middle vs low) = 8.715). The positive expression rate of CDK4 was significantly higher in high (78.6%, 11/14) and middle GAS groups (78.3%, 18/23) than in low GAS group (42.9%, 18/42) (P<0.05, c2(high vs low) = 5.364; P<0.01, c2(middle vs low) = 7.539). The positive expression rate of cyclin E was prominently higher in low SS group (53.3%, 24/45) than in high (9.1%, 1/11) and middle (21.7%, 5/23) SS groups (P<0.05, c2(high vs low) = 5.325; P<0.05, c2(middle vs low) = 6.212). The positive expression rate of CDK2 was significantly higher in low SS group (77.8%, 35/45) than in high SS group (27.3%, 3/11) (P<0.01, c2(high vs low) = 8.151). There was a significant positive correlation between the integral ratio of GAS to SS and the semi-quantitative integral of cyclin D1, cyclin E, cyclin A, CDK2, CDK4 (P<0.05, (D1)r(s) = 0.252; P<0.01, (E)r(s) = 0.387; P<0.01, (A)r(s) = 0.466; P<0.01, (K2)r(s) = 0.519; P<0.01, (K4)r(s) = 0.434).
CONCLUSION: The regulation and control of gastrin, SS in colorectal cancer cell growth may be directly related to the abnormal expressions of cyclins D1, A, E, and CDK2, CDK4. The regulatory site of GAS in the cell cycle of colorectal carcinoma may be at the G(1), S and G(2) phases. The regulatory site of SS may be at the entrance of S phase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437675      PMCID: PMC4725074          DOI: 10.3748/wjg.v11.i45.7211

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  53 in total

Review 1.  Cell cycle regulation and apoptosis.

Authors:  K L King; J A Cidlowski
Journal:  Annu Rev Physiol       Date:  1998       Impact factor: 19.318

Review 2.  Cell cycle checkpoints: preventing an identity crisis.

Authors:  S J Elledge
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

3.  ras p21 expression in the progression of breast cancer.

Authors:  F B Fromowitz; M V Viola; S Chao; S Oravez; Y Mishriki; G Finkel; R Grimson; J Lundy
Journal:  Hum Pathol       Date:  1987-12       Impact factor: 3.466

4.  Effects of proglumide, a gastrin receptor antagonist, on human large intestine carcinoma SW480 cell line.

Authors:  K Shen; S He; Y He
Journal:  Chin Med J (Engl)       Date:  1998-12       Impact factor: 2.628

Review 5.  Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.

Authors:  T Owa; H Yoshino; K Yoshimatsu; T Nagasu
Journal:  Curr Med Chem       Date:  2001-10       Impact factor: 4.530

Review 6.  Small molecule modulators of cyclin-dependent kinases for cancer therapy.

Authors:  A M Senderowicz
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

7.  Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines.

Authors:  Zahia Sadji-Ouatas; Malika Lasfer; Sophie Julien; Gérard Feldmann; Florence Reyl-Desmars
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

8.  Molecular aspects of the mammalian cell cycle and cancer.

Authors:  T Sandal
Journal:  Oncologist       Date:  2002

Review 9.  Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma.

Authors:  Yasusei Kudo; Shojiro Kitajima; Ikuko Ogawa; Mutsumi Miyauchi; Takashi Takata
Journal:  Oral Oncol       Date:  2005-02       Impact factor: 5.337

10.  COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer.

Authors:  M Yao; D H Song; B Rana; M M Wolfe
Journal:  Br J Cancer       Date:  2002-08-27       Impact factor: 7.640

View more
  4 in total

1.  Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth of large intestinal carcinoma.

Authors:  Jia-Ding Mao; Pei Wu; Jian-Xiong Huang; Jian Wu; Guang Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 2.  Gastrin - active participant or bystander in gastric carcinogenesis?

Authors:  Susan A Watson; Anna M Grabowska; Mohamad El-Zaatari; Arjun Takhar
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

3.  Peristalsis in the junction region of the Drosophila larval midgut is modulated by DH31 expressing enteroendocrine cells.

Authors:  Dennis R LaJeunesse; Brooke Johnson; Jason S Presnell; Kathleen Kay Catignas; Grzegorz Zapotoczny
Journal:  BMC Physiol       Date:  2010-08-10

4.  Relationship between expression of gastrin, somatostatin, Fas/FasL and caspases in large intestinal carcinoma.

Authors:  Jia-Ding Mao; Pei Wu; Ying-Lin Yang; Jian Wu; He Huang
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.